Phase I trials have shown the safety of the combination of olaparib with PI3K inhibitors (buparlisib and alperlisib), and preliminary evidence for activity was suggested, with response rates ranging from 29 to 36% in ovarian cancer patients (65, 66). Here, PIK3CA is linked to ovarian carcinoma.